Telix Pharmaceuticals reported total assets of $1361.85M and total liabilities of $874.18M for the quarter ended Jun 2026. This balance sheet covers 4 quarters of results from Dec 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Dec2023 | Dec2024 | Dec2025 | Jun2026 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & EquivalentsCash & Equiv. | 80.23M | 464.54M | 141.87M | 251.91M |
| Short-term InvestmentsInvestments (Current) | 7.98M | 36.68M | 37.09M | 40.41M |
| Cash & Current Investments | 88.21M | 501.22M | 178.96M | 292.32M |
| Receivables - NetNet Receivables | 42.52M | 91.33M | 129.20M | 163.56M |
| Receivables - OtherOther Receivables | 442.88M | |||
| Receivables | 42.52M | 91.33M | 129.20M | 606.44M |
| Raw Materials | 5.01M | 9.41M | ||
| Finished Goods | 2.38M | 9.18M | ||
| Inventory | 11.27M | 24.94M | 37.08M | 39.03M |
| Prepaid Assets | 12.71M | 13.81M | 16.09M | 26.69M |
| Current Assets | 151.36M | 600.70M | 330.28M | 488.02M |
| Non-Current Assets | ||||
| Property, Plant & Equipment (Net)PP&E (Net) | 112.92M | 390.98M | 833.71M | 873.83M |
| Long-Term Investments | 189.36M | 342.43M | -1.00M | |
| Goodwill | 66.59M | 198.99M | ||
| Intangibles | 71.39M | 272.13M | ||
| Goodwill & Intangibles | 71.39M | 272.13M | 592.82M | 584.61M |
| Long-Term Deferred Tax | 13.31M | 30.56M | 59.35M | 85.30M |
| Other Non-Current Assets | 0.38M | 16.08M | 28.82M | 33.88M |
| Non-Current Assets | 112.92M | 390.98M | 6.92M | 873.83M |
| Assets | 264.27M | 991.68M | 1,163.99M | 1,361.85M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payables | 53.19M | 91.51M | 150.35M | 168.97M |
| Notes Payables | 0.63M | 12.42M | 13.11M | 11.51M |
| Payables | 53.82M | 103.92M | 163.46M | 180.48M |
| Accumulated Expenses | 0.21M | 0.33M | 0.44M | 0.61M |
| Other Accumulated Expenses | 86.25M | 72.45M | ||
| Current Leases | 5.00M | 5.32M | 56.53M | 59.56M |
| Current Taxes | 12.48M | 31.77M | 30.74M | 33.85M |
| Current Deferred Revenue | 7.16M | 7.36M | 0.40M | 0.39M |
| Total Current Liabilities | 107.46M | 216.40M | 231.62M | 242.34M |
| Non-Current Liabilities | ||||
| Non-Current Debt | 5.34M | 360.87M | 391.91M | 504.88M |
| Pension | 9.06M | 14.93M | 19.37M | 20.29M |
| Non-Current Deferred Tax LiabilityNon-Current Deferred Tax | 6.13M | 44.71M | 43.30M | |
| Operating Leases | 0.39M | 1.63M | 5.55M | 3.92M |
| Other Non-Current Liabilities | 24.19M | 56.18M | 3.52M | 3.22M |
| Total Non-Current Liabilities | 59.88M | 403.69M | 516.99M | 631.83M |
| Total Liabilities | 167.34M | 620.09M | 748.61M | 874.18M |
| Shareholder's Equity | ||||
| Total Debt | 5.97M | 373.29M | 405.02M | 516.38M |
| Common Equity | 96.94M | 371.59M | 415.38M | 487.68M |
| Liabilities and Shareholders Equity | 264.27M | 991.68M | 1,163.99M | 1,361.85M |
| Retained Earnings | -171.64M | -139.27M | -154.54M | -110.90M |